<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831959</url>
  </required_header>
  <id_info>
    <org_study_id>EF-25 METIS</org_study_id>
    <nct_id>NCT02831959</nct_id>
  </id_info>
  <brief_title>Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).</brief_title>
  <official_title>Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, randomized controlled phase III trial, to test the efficacy,&#xD;
      safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic&#xD;
      radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to&#xD;
      supportive treatment alone. The device is an experimental, portable, battery operated device&#xD;
      for chronic administration of alternating electric fields (termed TTFields or TTF) to the&#xD;
      region of the malignant tumor, by means of surface, insulated electrode arrays.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAST PRE-CLINICAL AND CLINICAL EXPERIENCE:&#xD;
&#xD;
      The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in&#xD;
      vitro and in vivo NSCLC pre-clinical models both as a single modality treatment and in&#xD;
      combination with chemotherapies. TTFields have also shown to inhibit metastatic spread of&#xD;
      malignant melanoma in in vivo experiment.&#xD;
&#xD;
      In a pilot study, 42 patients with advanced NSCLC who had tumor progression after at least&#xD;
      one line of prior chemotherapy, received pemetrexed together with TTFields (150 kHz) applied&#xD;
      to the chest and upper abdomen until disease progression (Pless M., et al., Lung Cancer&#xD;
      2011). Efficacy endpoints were remarkably high compared to historical data for pemetrexed&#xD;
      alone.&#xD;
&#xD;
      In addition, a phase III trial of Optune® (200 kHz) as monotherapy compared to active&#xD;
      chemotherapy in recurrent glioblastoma patients showed TTFields to be equivalent to active&#xD;
      chemotherapy in extending survival, associated with minimal toxicity, good quality of life,&#xD;
      and activity within the brain (14% response rate) (Stupp R., et al., EJC 2012). Finally, a&#xD;
      phase III trial of Optune® combined with maintenance temozolomide compared to maintenance&#xD;
      temozolomide alone has shown that combined therapy led to a significant improvement in both&#xD;
      progression free survival and overall survival in patients with newly diagnosed glioblastoma&#xD;
      without the addition of high grade toxicity and without decline in quality of life (Stupp R.,&#xD;
      et al., JAMA 2015).&#xD;
&#xD;
      Applying TTFields at 150 kHz to the brain for the treatment of 1-5 brain metastasis from&#xD;
      NSCLC using the NovoTTF-100M device has been demonstrated to be safe in a pilot study, where&#xD;
      patients were randomized after local therapy of their brain metastasis by neurosurgery and/or&#xD;
      stereotactic radiosurgery to receive either NovoTTF-100M treatment or supportive care alone.&#xD;
      Eighteen (18) patients have been enrolled in the study. There have been no device-related&#xD;
      serious adverse events (SAE) reported to date (Brozova H., et al., Neuro Oncol 2016).&#xD;
&#xD;
      DESCRIPTION OF THE TRIAL:&#xD;
&#xD;
      All patients included in this trial are patients with 1-10 brain metastases from NSCLC which&#xD;
      are amenable to stereotactic radiosurgery (SRS). In addition, all patients must meet all&#xD;
      eligibility criteria.&#xD;
&#xD;
      Eligible patients will be randomly assigned to one of two groups:&#xD;
&#xD;
        1. Patients undergo SRS followed by TTFields using the NovoTTF-100M System&#xD;
&#xD;
        2. Patients undergo SRS alone and receive supportive care.&#xD;
&#xD;
      Patients in both arms of the study may receive systemic therapy for their NSCLC at the&#xD;
      discretion of their treating physician.&#xD;
&#xD;
      Patients will be randomized at a 1:1 ratio. Baseline tests will be performed in patients&#xD;
      enrolled in both arms. If assigned to the NovoTTF-100M group, the patients will be treated&#xD;
      continuously with the device until second intracranial progression.&#xD;
&#xD;
      On both arms, patients who recur anywhere in the brain will be offered one of the following&#xD;
      salvage treatments (according to local practice) including, but not limited to:&#xD;
&#xD;
        -  Surgery&#xD;
&#xD;
        -  Repeat SRS&#xD;
&#xD;
        -  Whole brain radiotherapy (WBRT)&#xD;
&#xD;
      Patients on the control arm will be offered to cross over to the NovoTTF-100M arm of the&#xD;
      study and receive TTFields after salvage therapy for second intracranial progression if the&#xD;
      investigator believes it is in the best interest of the patient and patient agrees.&#xD;
&#xD;
      SCIENTIFIC BACKGROUND:&#xD;
&#xD;
      Electric fields exert forces on electric charges similar to the way a magnet exerts forces on&#xD;
      metallic particles within a magnetic field. These forces cause movement and rotation of&#xD;
      electrically charged biological building blocks, much like the alignment of metallic&#xD;
      particles seen along the lines of force radiating outwards from a magnet.&#xD;
&#xD;
      Electric fields can also cause muscles to twitch and if strong enough may heat tissues.&#xD;
      TTFields are alternating electric fields of low intensity. This means that they change their&#xD;
      direction repetitively many times a second. Since they change direction very rapidly (150&#xD;
      thousand times a second), they do not cause muscles to twitch, nor do they have any effects&#xD;
      on other electrically activated tissues in the body (brain, nerves and heart). Since the&#xD;
      intensities of TTFields in the body are very low, they do not cause heating.&#xD;
&#xD;
      The breakthrough finding made by Novocure was that finely tuned alternating fields of very&#xD;
      low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in&#xD;
      the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are&#xD;
      multiplying, TTFields cause electrically-charged cellular components of these cells to change&#xD;
      their location within the dividing cell, disrupting their normal function and ultimately&#xD;
      leading to cell death.. In addition, cancer cells also contain miniature building blocks&#xD;
      which act as tiny motors in moving essential parts of the cells from place to place. TTFields&#xD;
      interfere with the normal orientation of these tiny motors related to other cellular&#xD;
      components since they are electrically-charged as well. As a result of these two effects,&#xD;
      tumor cell division is slowed, results in cellular death or reverses after continuous&#xD;
      exposure to TTFields.&#xD;
&#xD;
      Other cells in the body (normal healthy tissues) are affected much less than cancer cells&#xD;
      since they multiply at a much slower rate if at all. In addition TTFields can be directed to&#xD;
      a certain part of the body, leaving sensitive areas out of their reach. Finally, the&#xD;
      frequency of TTFields applied to each type of cancer is specific and may not damage normally&#xD;
      dividing cells in healthy tissues.&#xD;
&#xD;
      In conclusion, TTFields hold the promise of serving as a brand new treatment for brain&#xD;
      metastases from NSCLC with very few side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to intracranial progression</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neurocognitive failure</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by cognitive decline on a battery of tests: Hopkins Verbal Learning Test (HVLT-R) free recall, delayed recall, and delayed recognition; Controlled Oral Word Association Test (COWAT); and Trail Making Tests (TMT) Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response in the brain</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second intracranial progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first and second intracranial progression evaluated in two cohorts, 1-4 brain metastases and 5-10 brain metastases.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intracranial progression at 2, 4, 6, 8, 10, 12 months</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline in cognitive function at 2, 4, 6, 8, 10, 12 months</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by HVLT-R free recall, delayed recall, and delayed recognition; COWAT; and TMT Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive failure-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Defined from the date of first SRS treatment to neurocognitive failure (as measured by HVLT-R free recall, delayed recall, and delayed recognition; COWAT; and TMT Parts A and B) or death (whichever occurs first), censored at the last neurocognitive assessment on which the patient was reported alive without neurocognitive failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using the EORTC QLQ C30 with BN20 addendum</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity during NovoTTF-100M treatment based on incidence and severity of treatment emergent adverse events as evaluated using the CTCAE version 4.0</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Brain Metastases From Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>NovoTTF-100M device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-100M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-100M device</intervention_name>
    <arm_group_label>NovoTTF-100M device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Standard of Care</intervention_name>
    <arm_group_label>Best Standard of Care</arm_group_label>
    <arm_group_label>NovoTTF-100M device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age and older&#xD;
&#xD;
          2. Life expectancy of ≥ 3 months&#xD;
&#xD;
          3. New diagnosis of brain metastases from a histologically or cytologically confirmed&#xD;
             primary or metastatic NSCLC tumor within 5 years of registration on the study. If the&#xD;
             original histological proof of malignancy is greater than 5 years, then pathological&#xD;
             confirmation is required (i.e.: from extra-cranial or intracranial disease).&#xD;
&#xD;
          4. Karnofsky performance status (KPS) ≥ 70&#xD;
&#xD;
          5. 1 inoperable brain metastasis or 2- 10 brain lesions per screening MRI, confirmed by&#xD;
             contrast enhanced MRI amenable to SRS according to the following criteria:&#xD;
&#xD;
               1. largest tumor volume &lt; 10 cc&#xD;
&#xD;
               2. longest tumor diameter &lt; 3 cm&#xD;
&#xD;
               3. Cumulative volume of all tumors ≤ 15 cc&#xD;
&#xD;
          6. At least one measurable disease per study protocol&#xD;
&#xD;
          7. Patients must be receiving optimal therapy for their extracranial disease according to&#xD;
             local practice at each center. Patients may continue on systemic therapy while&#xD;
             receiving TTFields.&#xD;
&#xD;
          8. Able to operate the NovoTTF-100M device independently or with the help of a caregiver&#xD;
&#xD;
          9. Clinical trials prior to enrollment are allowed, as long as no brain directed therapy&#xD;
             was included (current treatment trials are exclusionary)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are known to have somatic tumor mutations in the following genes, for&#xD;
             which targeted agents are available that directly affect the treatment of brain&#xD;
             metastasis: Anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR),&#xD;
             ROS-1 proto-oncogene, and proto-oncogene B-RAF&#xD;
&#xD;
          2. Patients who have a single, operable brain metastasis&#xD;
&#xD;
          3. Patients with significant edema leading to risk of brain herniation&#xD;
&#xD;
          4. Patients with midline shift &gt; 10mm&#xD;
&#xD;
          5. Patients with intractable seizures&#xD;
&#xD;
          6. Leptomeningeal metastases&#xD;
&#xD;
          7. Recurrent brain metastases&#xD;
&#xD;
          8. Prior WBRT for newly diagnosed brain metastases&#xD;
&#xD;
          9. Severe comorbidities:&#xD;
&#xD;
               1. Clinically-significant inadequate hematological, hepatic and renal function,&#xD;
                  defined as: Neutrophil count &lt; 1.5 x 10 9/L and platelet count &lt; 100 x 10^9/L;&#xD;
                  bilirubin &gt; 1.5 x upper limit of normal (ULN); aspartate transaminase (AST)&#xD;
                  and/or alanine aminotransferase (ALT) &gt; 2.5 x ULN or &gt; 5 x ULN if patient has&#xD;
                  documented liver metastases; and serum creatinine &gt; 1.5 x ULN&#xD;
&#xD;
               2. History of significant cardiovascular disease unless the disease is well&#xD;
                  controlled. Significant cardiac disease includes second/third degree heart block;&#xD;
                  significant ischemic heart disease; poorly controlled hypertension; congestive&#xD;
                  heart failure of the New York Heart Association (NYHA) Class II or worse (slight&#xD;
                  limitation of physical activity; comfortable at rest, but ordinary activity&#xD;
                  results in fatigue, palpitation or dyspnea).&#xD;
&#xD;
               3. History of arrhythmia that is symptomatic or requires treatment. Patients with&#xD;
                  atrial fibrillation or flutter controlled by medication are not excluded from&#xD;
                  participation in the study.&#xD;
&#xD;
               4. History of cerebrovascular accident (CVA) within 6 months prior to randomization&#xD;
                  or that is not stable&#xD;
&#xD;
               5. Active infection or serious underlying medical condition that would impair the&#xD;
                  ability of the patient to received protocol therapy&#xD;
&#xD;
               6. History of any psychiatric condition that might impair patient's ability to&#xD;
                  understand or comply with the requirements of the study or to provide consent&#xD;
&#xD;
         10. Implantable electronic medical devices in the brain&#xD;
&#xD;
         11. Known allergies to medical adhesives or hydrogel&#xD;
&#xD;
         12. Currently pregnant or breastfeeding&#xD;
&#xD;
         13. Planned concurrent brain directed therapy (beyond SRS and NovoTTF-100M as per&#xD;
             protocol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minesh Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Cancer Institute, Miami FL USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center, Houston TX USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinai Gondi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Medicine Cancer Center, Warenville IL USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manmeet Ahluwalia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic, Cleveland OH USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa Bagulho</last_name>
    <phone>+1.603.206.2337</phone>
    <email>clinicaltrials@novocure.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tijy John</last_name>
    <phone>1.603.206.2337</phone>
    <email>clinicaltrials@novocure.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adelyn Gillion</last_name>
      <phone>205-975-3019</phone>
      <email>AGillion@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>John Fiveash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grandview Medical Center - Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243-3326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer De Los Santos</last_name>
      <phone>205-971-1800</phone>
      <email>jennifer.delossantos@grandviewhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer De Los Santos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013-4407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekokobe Fonkem</last_name>
      <phone>602-406-7409</phone>
      <email>ekokobe.fonkem@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Amir Azadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Watkin</last_name>
      <phone>855-776-0015</phone>
      <email>Sio.terence@mayo.edu</email>
    </contact>
    <contact_backup>
      <phone>(480) 342-6887</phone>
      <email>watkin.shelby@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Terence Sio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MemorialCare Cancer Institute</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Zuniga, CRC</last_name>
      <phone>562-933-7866</phone>
      <phone_ext>37846</phone_ext>
      <email>jzuniga@memorialcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Lissette Rosario-Remigio, CRC</last_name>
      <phone>562-933-7863</phone>
      <email>lrosarioremigio@memorialcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Linda Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Lichti</last_name>
      <phone>714-734-6200</phone>
      <phone_ext>40838</phone_ext>
      <email>christine.lichti@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Lars Anker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Redwood City</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Mendelssohn, CCRC</last_name>
      <phone>650-299-4165</phone>
      <email>nancy.d.mendelssohn@kp.org</email>
    </contact>
    <investigator>
      <last_name>Scott Peak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dignity Health - Mercy Cancer Centers</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Diorio, BSN</last_name>
      <phone>916-863-8731</phone>
      <email>dawn.diorio@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Lemieux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Cunanan</last_name>
      <phone>916-973-4885</phone>
      <email>renee.j.cunanan@kp.org</email>
    </contact>
    <investigator>
      <last_name>Enrico Lallana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp HealthCare</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy King, CRC</last_name>
      <phone>858-939-5052</phone>
      <email>amy.king@sharp.com</email>
    </contact>
    <investigator>
      <last_name>Siavash Jabbari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luchia Andemicael, CRC</last_name>
      <phone>415-476-8099</phone>
      <email>luchia.andemicael@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Steve Braunstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Harrell</last_name>
      <phone>904-953-8183</phone>
      <email>Harrell.Anna@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Trifiletti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Kudryashev</last_name>
      <phone>786-527-8809</phone>
      <email>AlexKu@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Minesh Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adult Oncology Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Sanders, MBA</last_name>
      <phone>321-841-3812</phone>
      <email>Kathleen.Sanders@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer Tseng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Manchola Orozco</last_name>
      <phone>321-841-7293</phone>
      <email>Carolina.Manchola-Orozco@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Naren Ramakrishna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center INC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaneska Chacin</last_name>
      <phone>561-447-0614</phone>
      <phone_ext>ext102</phone_ext>
      <email>vchacin@brcrglobal.com</email>
    </contact>
    <investigator>
      <last_name>Jason Tache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Brain Tumor Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Arabnia</last_name>
      <phone>404-425-7943</phone>
      <email>ali.arabnia@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Adam Nowlan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404-6220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hasselle</last_name>
      <phone>912-350-8490</phone>
      <email>Michael.hasselle@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Michael Hasselle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CDH-Delnor Health System</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Smith, MS, CCRC</last_name>
      <phone>603-352-5360</phone>
      <email>Donald.Smith@CadenceHealth.Org</email>
    </contact>
    <investigator>
      <last_name>Vinai Gondi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville-James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-5700</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goetz Kloecker</last_name>
    </contact>
    <investigator>
      <last_name>Goetz Kloecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neydin Osorio</last_name>
      <phone>504-703-5577</phone>
      <email>neydin.tejeda@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Marcus Ware, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willis-Knighton Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Barrow</last_name>
      <phone>318-212-4639</phone>
    </contact>
    <investigator>
      <last_name>Chiachien Jake Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Romar</last_name>
      <phone>443-643-1877</phone>
      <email>lromar@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Eggleston</last_name>
      <phone>410-328-7586</phone>
      <email>caitlineggleston@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Mishra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Schmidt</last_name>
      <phone>301-295-6814</phone>
      <email>virginia.f.schmidt3.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Brett Theeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Lawlor</last_name>
      <phone>617-636-8897</phone>
      <email>clawlor3@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Suriya Jeyapalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Shapiro;</last_name>
      <phone>617-975-7473</phone>
      <email>eshapir1@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson, CRC</last_name>
      <phone>313-576-9806</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Michael Dominello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital - Givens Brain Tumor Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Trusheim, MD</last_name>
      <phone>612-863-3452</phone>
      <email>john.trusheim@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Nasseff Neuroscience Institute ANW Brain Tumor Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Hultman</last_name>
      <phone>612-863-3308</phone>
      <email>Meghan.hultman@allina.com</email>
    </contact>
    <investigator>
      <last_name>John Trusheim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center (UMMC) - Fairview - Masonic Cancer Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Sperduto</last_name>
    </contact>
    <investigator>
      <last_name>Emil Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Barnes</last_name>
      <phone>601-815-4540</phone>
      <email>jbarnes@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center, University of Missouri Healthcare</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Holm</last_name>
      <phone>573-882-9165</phone>
      <email>HolmL@health.missouri.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Biedermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Research | Mercy Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Engemann, CRC</last_name>
      <phone>636-390-1452</phone>
      <email>miriam.engemann@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Craft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amil Trujillo-King</last_name>
      <phone>775-982-5733</phone>
      <email>amil.trujillo-king@renown.org</email>
    </contact>
    <investigator>
      <last_name>Garrett Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Majka;</last_name>
      <phone>856-735-6537</phone>
      <email>barbara@cooperhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Kubicek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC - Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Correi Moore</last_name>
      <phone>919-966-4432</phone>
      <email>correai_moore@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Simon Khagi, MD</last_name>
      <phone>919-966-4432</phone>
      <email>skhagi@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Khagi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tameka Little</last_name>
      <phone>252-847-0989</phone>
      <email>tameka.little@vidanthealth.com</email>
    </contact>
    <investigator>
      <last_name>K. Stuart Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Bonomi</last_name>
      <phone>336-716-0477</phone>
      <phone_ext>x5772</phone_ext>
      <email>mbonomi@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Robinson</last_name>
      <phone>216-445-8624</phone>
      <email>robinsk2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Manmeet Ahluwalia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyla Lindberg</last_name>
      <phone>503-216-1191</phone>
      <email>Kyla.Lindberg@providence.org</email>
    </contact>
    <investigator>
      <last_name>Ricky Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Whitmire</last_name>
      <phone>570-214-2834</phone>
      <email>awhitmire@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Gatson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kastura</last_name>
      <phone>401-793-4285</phone>
      <email>michaela.kastura@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Heinrich Elinzano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina- Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-8900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Lindhorst</last_name>
      <email>LINDHORS@MUSC.EDU</email>
    </contact>
    <investigator>
      <last_name>Scott Lindhorst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlanger Baroness Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Graham</last_name>
      <email>robert.graham@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>THOMAS DEVLIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Mayo, CCRP</last_name>
      <phone>910-683-0055</phone>
      <phone_ext>63005</phone_ext>
      <email>ramayo@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Ballo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mischer Neuroscience Associates - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Baskin</last_name>
      <phone>713-441-3800</phone>
      <email>jabaskin@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Ivo Tremont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy DeCastro</last_name>
      <phone>214-491-5845</phone>
      <email>christy.decastro@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anand Shivnani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue &quot;Annie&quot; Feng</last_name>
      <phone>469-467-4340</phone>
      <email>yue.feng@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Petrikas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center - Temple</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712-8897</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Mims</last_name>
      <email>rmims@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Lynne Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215-5221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Bobustuc</last_name>
      <email>george.bobustuc@aurora.org</email>
    </contact>
    <investigator>
      <last_name>George Bobustuc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Freyschlag, MD</last_name>
      <phone>+43 51250427453</phone>
      <email>christian.freyschlag@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christian Freyschlag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski EAD, Department of Medical Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+359 898 567 892</phone>
      <email>bostro@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Bozhil Robev, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sofiamed, Department of Medical Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+359 879 202 386</phone>
      <email>md_margarita@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Margarita Taushanova-Hadzhieva, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancercare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Dyck</last_name>
      <phone>(204) 787-2127</phone>
      <email>kdyck5@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Saranya Kakumanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dounia Kellou</last_name>
      <phone>(514) 890-8000</phone>
      <phone_ext>24506</phone_ext>
      <email>dounia.kellou.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Roberge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia Shtepman</last_name>
      <phone>(514) 340-8222</phone>
      <phone_ext>26801</phone_ext>
      <email>sofia.Shtepman.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Thierry Muanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le CIUSSS de I'Est-de-L'ile de Montreal - Hopital Moaisonneuve Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T-2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Abi Saad</last_name>
      <phone>(514) 252-3400</phone>
      <phone_ext>3227</phone_ext>
      <email>josee.abi-saad.cemtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Pierre Chabot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(CHUS) Centre Hospitalier Universitaire de Sherbrooke, Service de Neurochirurgie</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yangqing Cao</last_name>
      <email>13902400598@126.com</email>
    </contact>
    <investigator>
      <last_name>Xicheng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desheng Hu, MD</last_name>
      <phone>18378836669</phone>
      <email>254130140@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Chen</last_name>
      <phone>13071260790</phone>
      <email>chgafly@163.com</email>
    </contact>
    <investigator>
      <last_name>Conghua Conghua Xie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaiyun Yu</last_name>
      <email>kaiyun.yu@tigermedgrp.com</email>
    </contact>
    <investigator>
      <last_name>Jing Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhao</last_name>
      <email>qwu@suda.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Songbing Qin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Zhao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Wang</last_name>
      <email>wangyi@163.com</email>
    </contact>
    <investigator>
      <last_name>Yi Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ligang Xing</last_name>
      <phone>86 15553181309</phone>
      <email>xinglg@medmail.com</email>
    </contact>
    <investigator>
      <last_name>Jinming Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qingdao Center Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaotao Zhang</last_name>
      <phone>186 6971 0019</phone>
      <email>SABR@VIP.163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaotao Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zigong Fourth People's Hospital</name>
      <address>
        <city>Zigong</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei You</last_name>
      <phone>158 9220 9705</phone>
      <email>youwei85@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jidong Miao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Xuhui District</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Yang</last_name>
      <phone>173121296901</phone>
      <email>ntgeorge@qq.com</email>
    </contact>
    <investigator>
      <last_name>Zhengfei Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital, Zhejiang Province</name>
      <address>
        <city>Zhejiang</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongquing Lv</last_name>
      <email>dani.dai@tigermedgrp.com</email>
    </contact>
    <contact_backup>
      <last_name>Lingyan Ye</last_name>
      <email>Yely6371@enzemed.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxia Wang</last_name>
      <email>lily31415926@126.com</email>
    </contact>
    <investigator>
      <last_name>Hongquing Zhuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Dong</last_name>
      <email>drlhdong@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuyu Zhang</last_name>
      <email>zhangyuyu@jlu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Xingtai Medical College</name>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Ni</last_name>
      <email>nijie@126.com</email>
    </contact>
    <investigator>
      <last_name>Lijun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiochirugia Zagreb</name>
      <address>
        <city>Sveta Nedelja</city>
        <zip>10431</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Mišir Krpan, Dr.</last_name>
      <phone>+385 91 5411278</phone>
      <email>anamisirkrpan@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ana Mišir Krpan, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Gombert</last_name>
      <phone>+ 33 320446611</phone>
      <email>Camille.GOMBERT@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Emilie Le Rhun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clairval Hospital Center</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie Bialecki</last_name>
      <phone>+33 4 91 17 14 28</phone>
      <email>emilie.bialecki@outlook.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Metellus, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pitié-Salpétriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Feuvret, Dr.</last_name>
      <phone>+33 142 178151</phone>
      <email>loic.feuvret@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc Feuvret, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Radioonkologie und Strahlentherapie der Charité Universitätsmedizin Berlin Campus Charité Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kaul</last_name>
      <email>david.kaul@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Dietrichs</last_name>
      <phone>+49 211 81 07471</phone>
      <email>Nicole.Dietrichs@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Sevens</last_name>
      <phone>+49 211 8117 881</phone>
      <email>Natalie.Sevens@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Sabel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Senckenbergisches Institut für Neuroonkologie, Zentrum der Neurologie und Neurochirurgie</name>
      <address>
        <city>Frankfurt am main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danijela Toth-Zuparic</last_name>
      <phone>069 630187711</phone>
      <email>Danijela.Toth-Zuparic@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Martin Voss, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale), Klinik für Innere Medizin IV, Hämatologie / Onkologie</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Rauch</last_name>
      <phone>+49 345-557-1954</phone>
      <email>jacqueline.rauch@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Jörn Rüssel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwok Cheun Dennis Leung</last_name>
      <email>leungkcd@ha.org.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologiai Osztaly, Balassa Janos Korhaz</name>
      <address>
        <city>Szekszárd</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousuf Al-Fahat</last_name>
      <email>yalfarhat@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geza Hetenyi Hospital-Clinic of Jasz-Nagykun-Szolnok County</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Csőszi</last_name>
      <phone>+36 20 9323256</phone>
      <email>dr.cstibor@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Tibor Csőszi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orit Kaidar-Person, Dr.</last_name>
      <phone>+ 972-58-6999640</phone>
      <email>o_person@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Orit Kaidar-Person, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-50-9010250</phone>
      <email>ALOS@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Alexander Lossos, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aron Popovtzer, Dr.</last_name>
      <phone>+972-3-9378004</phone>
      <email>aronp@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>aronp@clalit.org.il aronp@clalit.org.il, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leor Zach, Dr.</last_name>
      <phone>972-52-6667153</phone>
      <email>leor.zach@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Leor Zach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Blumenthal, Prof. Dr.</last_name>
      <phone>+972-3-6973494</phone>
      <email>deborahblumenthal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Deborah Deborah, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.S.G. Moscati Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialità</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale di Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Salmaggi, MD</last_name>
      <phone>+39 3333593768</phone>
      <email>a.salmaggi@asst-lecco.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Salmaggi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Messina AOU Policlinico &quot;G. Martino&quot;</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pontoriero, Dr.</last_name>
      <phone>+39 09 022 128 62</phone>
      <email>apontoriero@unime.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Antonio, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Airoldi, Dr.</last_name>
      <phone>+39 0116334134</phone>
    </contact>
    <investigator>
      <last_name>Mario Airoldi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marek Harat Private Practice, Neurosurgery and Radiation Oncology</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85357</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Harat, MD</last_name>
      <phone>+48 600411874</phone>
      <email>haratmaciej@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maciej Harat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Center</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Kukowska</last_name>
      <phone>+48 583492214</phone>
      <email>kukowska@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Szutowicz-Zielińska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudia Wesołowska</last_name>
      <phone>+48 61 8549038</phone>
      <email>claudiawesolowska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rodryg Ramlau, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Neuro-oncology, Neurosurgery Clinic, Clinical Center of Serbia</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ljubomir Kurij</last_name>
      <phone>+381 66 8402349</phone>
      <email>ljubomir_kurij@protonmail.com</email>
    </contact>
    <investigator>
      <last_name>Danica Grujicic, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catalan Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montse Ventura</last_name>
      <email>montseventura@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Anna Maria Lucas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Navarcorena</last_name>
      <email>enavarco@unav.es</email>
    </contact>
    <investigator>
      <last_name>Marta Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95.</citation>
    <PMID>15126372</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.</citation>
    <PMID>19387848</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.</citation>
    <PMID>26658786</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, Kirson ED, Palti Y. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014 Oct;41 Suppl 6:S35-41. doi: 10.1053/j.seminoncol.2014.09.006. Epub 2014 Sep 8.</citation>
    <PMID>25213867</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.</citation>
    <PMID>26670971</PMID>
  </reference>
  <reference>
    <citation>Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013 Sep;81(3):445-450. doi: 10.1016/j.lungcan.2013.06.025. Epub 2013 Jul 23.</citation>
    <PMID>23891283</PMID>
  </reference>
  <reference>
    <citation>Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun;16(6):e270-8. doi: 10.1016/S1470-2045(15)70057-4. Epub 2015 May 27. Review.</citation>
    <PMID>26065612</PMID>
  </reference>
  <reference>
    <citation>Brozova H, Lucas A, Salmaggi A, Vymazal J. COMET: A phase II randomized study of TTFields versus supportive care in non-small cell lung cancer patients with 1-5 brain metastases - initial safety results. Neuro Oncol. 2015 Nov; 17 (suppl 5): v46. doi:10.1093/neuonc/nov208.6</citation>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Treatment</keyword>
  <keyword>Minimal toxicity</keyword>
  <keyword>TTFields</keyword>
  <keyword>TTF</keyword>
  <keyword>Tumor Treating Fields</keyword>
  <keyword>Novocure</keyword>
  <keyword>SRS</keyword>
  <keyword>Stereotactic radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

